title: [A case of multiple hepatic metastases of gastric cancer that showed complete regression by systemic chemotherapy using paclitaxel and UFT-E].
abstract: We report a case of gastric cancer with simultaneous multiple liver metastasis that was successfully treated by paclitaxel and UFT-E. A 54-year-old man with gastric cancer was admitted to our hospital for further examination and treatment. A type III gastric cancer was located in the lower to middle part of the gastric body. Abdominal CT revealed multiple liver metastases and lymph node metastases. Then, we performed distal gastrectomy and cholecystectomy. Postoperative pathological diagnosis was stage IV(a type 3 tumor( 78x65 mm), pT3, por 2, INF g, ly3, v0, pN2(+)(26/ 28), H1(bilobular multiple metastases), CY0, P0). Postoperatively, he was treated with S-1 po at 100 mg/body/day as first-line chemotherapy. Thirteen days after S-1 initiation, he was readmitted due to grade 3 diarrhea, and S-1 was immediately stopped. After his general condition was improved, paclitaxel was administered biweekly at a dose of 80 mg/m2. He was discharged after twice administration, and the regimen was continued at an outpatient clinic. Four months after the operation, abdominal computed tomography(CT)showed a remarkable reduction of the multiple liver metastases, and the serum levels of tumor markers(CEA, CA19-9)were reduced. Five months after the operation, the serum levels of tumor markers elevated again. Then, additional administration of UFT-E po(300 mg/body daily) was started. Seven months after the operation, abdominal CT showed a complete regression of the multiple liver metastasis, and the serum levels of tumor markers were also reduced within the normal range. During chemotherapy at an outpatient clinic, critical adverse effects did not appear. Paclitaxel or paclitaxel combined with UFT-E might be an effective regimen as second- or third-line chemotherapy for the liver metastases of gastric cancer.
authors: Division Digestive Surgery, Dept. of Surgery, Kyoto Prefectural University of Medicine, Japan.
authors: Hiroko
authors: H
authors: Okamura
authors: Hitoshi
authors: H
authors: Fujiwara
authors: Daisuke
authors: D
authors: Ichikawa
authors: Kazuma
authors: K
authors: Okamoto
authors: Shojiro
authors: S
authors: Kikuchi
authors: Takeshi
authors: T
authors: Kubota
authors: Hisashi
authors: H
authors: Ikoma
authors: Masayoshi
authors: M
authors: Nakanishi
authors: Toshiya
authors: T
authors: Ochiai
authors: Chouhei
authors: C
authors: Sakakura
authors: Yukihito
authors: Y
authors: Kokuba
authors: Hiroki
authors: H
authors: Taniguchi
authors: Teruhisa
authors: T
authors: Sonoyama
authors: Eigo
authors: E
authors: Otsuji
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*; D005641:Tegafur / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed; D014498:Uracil / Q000008:administration & dosage
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D005641:Tegafur; D014498:Uracil; D017239:Paclitaxel